EUCTR2004-004519-43-CZ进行中（未招募）1 期
Phase II, multicenter, randomised, double-blind, placebo-controlled, parallel group, dose-ranging study to determine the effect on MRI lesions and safety of RO0506997 in Relapsing Multiple Sclerosis
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Protocol section 4.1.1: MS-related Inclusion Criteria
- •1) Diagnosis of relapsing MS types 1-4 based on McDonald criteria” as revised in
- •2005 (Appendix 1), without taking into account the screening MRI results
- •2) EDSS score of = 6.5 (Appendix 2)
- •3) Between 12 months and 1 month previous: 1 or more MS attack (which has been
- •documented in prior medical records) or a brain MRI with a gadolinium-enhancing
- •lesion consistent with an MS lesion (based on radiology report or investigator review
- •Protocol section 4.1.3: Other Inclusion Criteria
- •1) Signed written informed consent
- •2) Men or women 18-59 years of age
- •i) If female: postmenopausal (i.e. spontaneous amenorrhea for the past year confirmed by an FSH level greater
- •than 40 mIU/mL unless the patient is receiving HRT), surgically sterile (i.e.
- •tubal ligation, hysterectomy) or if of childbearing potential, must use abstinence or two methods of contraception throughout the trial. These should include one primary (e.g. systemic hormonal contraception, vasectomy of the male partner) AND one secondary barrier method (e.g. latex condoms, spermicide) OR a double barrier method (e.g. latex condom plus spermicide (e.g. foam, suppository, gel cream)) may be used.
- •(1) Definition of postmenopausal for patients participating in the study at sites in Germany: spontaneous amenorrhea for 2 years, FSH levels > 40 m IU/mL and estrogen levels < 30pg/ml (unless the patient is receiving HRT and is over 55 years of age).
- •Protoocl section 4.2.1: Inclusion Criteria at Baseline:
- •1) Screen MRI meets the Paty criteria” of: = 4 T2 lesions or = 3 T2 lesions if at least 1 is periventricular. It is the responsibility of a site investigator to make this
- •determination.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Protocol section 4.1.2: MS-related Exclusion Criteria
- •1) MS attack or systemic corticosteroids within 1 month
- •2) MS treatments which are given to primarily treat symptoms:
- •a) Within 3 months: if part of an IRB/EC approved trial
- •b) Otherwise may remain on the regimen if it is unchanged within 1 month and is
- •unlikely to change before week 16. This includes cannabis-related agents as well
- •as categories such as over-the-counter, herbal and nutritional supplement.
- •The following refer to any other agents given to treat MS (approved or unapproved):
- •3) Within 3 months: interferon beta, glatiramer acetate, or plasmapheresis
- •4) Within 12 months: intravenous immunoglobulin, cytapheresis,
- •azathiaprine, cladribine, cyclophosphamide, methotrexate, mitoxantrone,
- •mycophenolate, pixantrone, sirolimus, tacrolimus or other agents typically used to
- •prevent transplant rejection or as cancer chemotherapy, excluding hormonal
- •5) Ever having received: natalizumab, stem cell or bone marrow transplant, total lymphoid irradiation,
- •vaccine therapy for MS or monoclonal antibodies whose effects may be longer than 1
- •year such as alemtuzumab, daclizumab or rituxan (rituximab)
- •6) Within 3 months: any other agents given for non-symptomatic treatment of MS which
- •were not included above in items 3-5 such as HMGCoA-reductase inhibitors,
- •glitazone”-type antidiabetics, 4-aminopyridine or products related to 4-
- •aminopyridine, antibiotics, hormone treatment, as well as categories such as overthe-
- •counter, herbal and nutritional supplement. However, if the agent is being taken
- •primarily to treat another medical condition, then it is allowed as long as the dose is
- •unchanged within 3 months and is unlikely to change before week 16
- •Protocol section 4.1.4: Other Exclusion Criteria
- •1) Women who are pregnant or may breastfeed before week 16
- •2) Within 1 month: an infection requiring systemic anti-infective treatment or a
- •vaccination. Exceptions are treatment of an uncomplicated urinary tract infection or
- •upper respiratory tract infection.
- •3) Within 3 months: participation in any IRB/EC investigational drug trial or treatment
- •with anti-TNF or other potentially immune modulating agents not already
- •4) Within 6 months: alcohol abuse or drug abuse as assessed by the investigator using, for example, DSM-IV criteria for substance abuse
- •5) History of HIV infection or Hepatitis C Infection, Tuberculosis (TB), or progressive multifocal leukoencephalopathy (PML)
- •6) History of hereditary or acquired immunodeficiency, except for that caused by
- •pharmaceutical intervention; or currently present hereditary or acquired
- •immunodeficiency, including that caused by pharmaceutical intervention
- •7) A medical or neurological condition a) that may significantly interfere with the
- •absorption of an oral medication, b) which is likely to require a new medication or
- •hospitalization over the next 6 months or c) that may interfere with the assessment
- •8) Presence of pacemakers or foreign metal objects in the eyes, skin, or body which
- •would contraindicate an MRI scan or renal impairement which would contraindicate gadolinium injection
- •9) Current or history of cancer, excluding localized non-melanoma skin cancer
- •Protocol section 4.2.2: Exclusion Criteria at Baseline
- •1) Since screening, except for the use of systemic corticosteroids for an MS attack (see section 5), use of any new treatment which has been approved for or is being
- •evaluated for an effect on MS
- •2) Since screening, developmen
研究者
相似试验
进行中（未招募）
不适用
Phase II, multicenter, randomised, double-blind, placebo-controlled, parallel group, dose-ranging study to determine the effect on MRI lesions and safety of RO0506997 in Relapsing Multiple SclerosisRelapsing Multiple SclerosisEUCTR2004-004519-43-GBF. Hoffmann-La Roche Ltd200
进行中（未招募）
1 期
Phase II, multicenter, randomised, double-blind, placebo-controlled, parallel group, dose-ranging study to determine the effect on MRI lesions and safety of RO0506997 in Relapsing Multiple SclerosisRelapsing Multiple SclerosisEUCTR2004-004519-43-SKF. Hoffmann-La Roche Ltd200
进行中（未招募）
不适用
Phase II, multicenter, randomised, double-blind, placebo-controlled, parallel group, dose-ranging study to determine the effect on MRI lesions and safety of RO0506997 in Relapsing Multiple SclerosisRelapsing Multiple SclerosisEUCTR2004-004519-43-DEF. Hoffmann-La Roche Ltd200
已完成
不适用
Phase II, multicentre, randomised, double-blind, placebo-controlled, pilot study to determine the efficacy, safety, tolerability and pharmacokinetics of intravesical PSD597 in reducing the pain of the bladder biopsy procedureISRCTN77602717Plethora Solutions Ltd (UK)40
进行中（未招募）
不适用
Safety and efficacy study of TRO40303 for reduction of reperfusion injury in patients undergoing Percutaneous Coronary Intervention for acute myocardial infarctioEUCTR2010-024616-33-SETROPHOS SA